Company intelligence / Profile preview

Full-Life Technologies

Shanghai, Shanghai, Chinafull-life.com ↗

Ownership: Private
Development stage: Other

Overview

The company’s lead candidate, ^225Ac-FL‑020 targeting PSMA in mCRPC, was progressing toward Phase I clinical trials as of early 2024. The company has raised over $110 million since its founding and aims to become a fully integrated radiopharmaceutical developer with end-to-end capabilities from R&D through manufacturing and commercialization. No published clinical results yet.

Therapeutic areas: Oncology
Modalities: Radionuclide Drug Conjugates (RDC)Radiotherapeutics (radioisotope-labeled peptides, small molecules, single domain antibodies)
Industry: Biotech

Drug pipeline

10 assets

225Ac-FL-020

9 more assets in the full pipeline.

Request access →

Partnerships

Major supply-chain partners for radioisotopes/logistics mentioned but not named specifically.

Beyond the preview

Go deeper on Full-Life Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Full-Life Technologies.

Explore the full profile